|Application ||IHC, IF, FC, E|
|Isotype||Human IgG4, kappa|
|Calculated MW||114536 Da|
|Other Names||Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e|
|Formulation||200 µg affinity purified human antibody in phosphate-buffered saline (PBS) containing 0.02% Proclin 300|
|Reconstitution & Storage||-20 °C|
|Precautions||Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Integrin alpha-5/beta-1 is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881).|
|Cellular Location||Membrane; Single-pass type I membrane protein. Cell junction, focal adhesion. Cell surface|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The antibody binds specifically to a5ß1 integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The a5ß1 integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.